The Antitumor Assessment Core Facility was established in 2003 to provide expert support for early discovery of effective antitumor agents and therapeutics. The Core provides resources, professional and technical expertise and advisory services related to the evaluation of agents with potential therapeutic activity, and works closely with investigators to establish in vivo mouse models for the design and execution of pharmacokinetic, toxicity and In vivo efficacy studies. As such, the Core provides a major vehicle to facilitate pre-clinical studies and is a major contributor to the translational mission of the Center. The Core also determines the best formulation, administration route, and treatment schedule for each new compound, either alone or in combination with other agents. The Core helps investigators to design and plan their experiments, prepare animal protocols and grant applications involving animal studies, and analyzes and summarizes data for publication. Importantly, the Core acts as a central coordinator for studies involving support from several core facilities (including Animal Imaging, Comparative Pathology, Tissue Procurement Service, Analytical Pharmacology, Organic Synthesis, Microarray, Radiation Facility, and Cytology) so that studies are carried out properly and in a time- and cost-efficient manner. The services and collaborative work provided by the Antitumor Assessment Core has supported the research of 56 investigators from 9 programs. A particularly exciting example of the work supported is: in 2010 the Core provided support services that were used by Dr. Charles Sawyer's group (ET and CBEP Programs) to develop ARN-509, an Androgen Receptor (AR) inhibitor targeting castration-resistant prostate cancer (CRPC), the most advanced form of this disease. This study has led to a Phase l/ll Clinical Trial currently ongoing at MSKCC. The Core undertook all the animal studies performed at MSKCC for this work.

Public Health Relevance

The Antitumor Assessment Core Facility provides support for the evaluation of effective antitumor agents and therapeutics and thereby directly advances the translational research activities of Memorial Sloan- Kettering Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-52
Application #
9406248
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
52
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Basaraba, Cale N; Westhoff, Carolyn L; Pike, Malcolm C et al. (2017) Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception 95:398-404
Hernandez, Jonathan M; Beylergil, Volkan; Goldman, Debra A et al. (2017) Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Ann Surg :
Argani, Pedram; Kao, Yu-Chien; Zhang, Lei et al. (2017) Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues. Am J Surg Pathol 41:1702-1712
Moore, Kathleen N; Martin, Lainie P; O'Malley, David M et al. (2017) Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 35:1112-1118
Lee, Ser Yee; Goh, Brian K P; Sadot, Eran et al. (2017) Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Ann Surg Oncol 24:202-210
Hyman, David M; Taylor, Barry S; Baselga, José (2017) Implementing Genome-Driven Oncology. Cell 168:584-599
Li, Gang G; Somwar, Romel; Joseph, James et al. (2017) Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clin Cancer Res 23:2981-2990
Bhagat, Tushar D; Zou, Yiyu; Huang, Shizheng et al. (2017) Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer. J Biol Chem 292:837-846
Prieto-Granada, Carlos N; Zhang, Lei; Antonescu, Cristina R et al. (2017) Primary cutaneous adenoid cystic carcinoma with MYB aberrations: report of three cases and comprehensive review of the literature. J Cutan Pathol 44:201-209
He, Mu; Agbu, Stephanie; Anderson, Kathryn V (2017) Microtubule Motors Drive Hedgehog Signaling in Primary Cilia. Trends Cell Biol 27:110-125

Showing the most recent 10 out of 7561 publications